Whether Organon & Co. (OGN) will fully recover and sustain its upward trajectory depends on its execution of long-term debt reduction, successful commercial launches of new pharmaceutical products, and effective mitigation of generic competition pressures on legacy brands. While value-focused investors highlight its strong operational cash flows and low valuation multiples as a foundation for recovery, bears point to ongoing execution risks and competitive headwinds in the pharmaceutical sector.